Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.51 Billion SEK | 25.18% |
| 2022 | 1.2 Billion SEK | 60.47% |
| 2021 | 753.8 Million SEK | 96.77% |
| 2020 | 383.09 Million SEK | 80.1% |
| 2019 | 212.7 Million SEK | 59.69% |
| 2018 | 133.19 Million SEK | 57.34% |
| 2017 | 84.65 Million SEK | 49.79% |
| 2016 | 56.51 Million SEK | 9.98% |
| 2015 | 51.38 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 485.29 Million SEK | 21.37% |
| 2024 Q2 | 540.53 Million SEK | 11.38% |
| 2023 Q1 | 366.42 Million SEK | -5.72% |
| 2023 FY | 1.51 Billion SEK | 25.18% |
| 2023 Q4 | 399.84 Million SEK | -8.97% |
| 2023 Q3 | 439.24 Million SEK | 32.97% |
| 2023 Q2 | 330.34 Million SEK | -9.85% |
| 2022 Q4 | 388.66 Million SEK | 33.12% |
| 2022 Q2 | 271.5 Million SEK | 5.45% |
| 2022 Q1 | 257.48 Million SEK | 1.65% |
| 2022 FY | 1.2 Billion SEK | 60.47% |
| 2022 Q3 | 291.96 Million SEK | 7.53% |
| 2021 Q4 | 253.31 Million SEK | 33.1% |
| 2021 Q1 | 150.78 Million SEK | 10.59% |
| 2021 Q2 | 159.39 Million SEK | 5.72% |
| 2021 FY | 753.8 Million SEK | 96.77% |
| 2021 Q3 | 190.31 Million SEK | 19.39% |
| 2020 Q1 | 72.8 Million SEK | 12.89% |
| 2020 Q2 | 66.56 Million SEK | -8.57% |
| 2020 FY | 383.09 Million SEK | 80.1% |
| 2020 Q4 | 136.34 Million SEK | 29.98% |
| 2020 Q3 | 104.89 Million SEK | 57.58% |
| 2019 Q4 | 64.48 Million SEK | 22.51% |
| 2019 Q2 | 52.82 Million SEK | 23.65% |
| 2019 Q3 | 52.63 Million SEK | -0.36% |
| 2019 FY | 212.7 Million SEK | 59.69% |
| 2019 Q1 | 42.72 Million SEK | -6.02% |
| 2018 Q4 | 45.46 Million SEK | 45.37% |
| 2018 FY | 133.19 Million SEK | 57.34% |
| 2018 Q3 | 31.27 Million SEK | 71.76% |
| 2018 Q2 | 18.2 Million SEK | -52.41% |
| 2018 Q1 | 38.25 Million SEK | -5.97% |
| 2017 Q3 | 17.47 Million SEK | 12.83% |
| 2017 Q1 | 11 Million SEK | 0.0% |
| 2017 Q2 | 15.48 Million SEK | 40.68% |
| 2017 Q4 | 40.68 Million SEK | 132.83% |
| 2017 FY | 84.65 Million SEK | 49.79% |
| 2016 FY | 56.51 Million SEK | 9.98% |
| 2015 FY | 51.38 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -3818.607% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | -370.98% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | -323.415% |
| Xintela AB (publ) | 57.31 Million SEK | -2541.894% |
| Active Biotech AB (publ) | 44.8 Million SEK | -3279.294% |
| Amniotics AB (publ) | 29.07 Million SEK | -5108.544% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -10233.912% |
| BioArctic AB (publ) | 89.62 Million SEK | -1589.478% |
| Camurus AB (publ) | 1.05 Billion SEK | -42.898% |
| Cantargia AB (publ) | 290.01 Million SEK | -422.117% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -6815.862% |
| CombiGene AB (publ) | 44.14 Million SEK | -3330.193% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -958.997% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -5245.654% |
| Genovis AB (publ.) | 88.19 Million SEK | -1616.87% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -1215.885% |
| Mendus AB (publ) | 129.13 Million SEK | -1072.575% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -20734.177% |
| Intervacc AB (publ) | 79.78 Million SEK | -1797.886% |
| Kancera AB (publ) | 63.07 Million SEK | -2300.602% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -27336.637% |
| LIDDS AB (publ) | 27.75 Million SEK | -5356.284% |
| Lipum AB (publ) | 37.3 Million SEK | -3958.831% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -20774.387% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -1014.124% |
| NextCell Pharma AB | -576.01 Thousand SEK | 262978.134% |
| OncoZenge AB (publ) | 15.9 Million SEK | -9420.453% |
| Saniona AB (publ) | 1.07 Million SEK | -140496.843% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -733.211% |
| Ziccum AB (publ) | 27.87 Million SEK | -5331.624% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -9132.535% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | -393.089% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -3451.858% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -8463.185% |
| Corline Biomedical AB | 30.16 Million SEK | -4919.318% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -2509.343% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -1720.664% |
| Aptahem AB (publ) | 10.01 Million SEK | -15022.705% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -1024.199% |
| Fluicell AB (publ) | 28.61 Million SEK | -5191.358% |
| Biovica International AB (publ) | 133.72 Million SEK | -1032.37% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -7551.481% |
| AcouSort AB (publ) | 25.87 Million SEK | -5751.863% |
| Abliva AB (publ) | 27.86 Million SEK | -5333.963% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -682.547% |
| 2cureX AB (publ) | 36.51 Million SEK | -4046.525% |
| I-Tech AB | 40.14 Million SEK | -3671.615% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | -76.186% |
| Cyxone AB (publ) | 28.21 Million SEK | -5266.938% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -1284.526% |
| Biosergen AB | 26.8 Million SEK | -5548.208% |
| Nanologica AB (publ) | 69.88 Million SEK | -2066.68% |
| SynAct Pharma AB | 224.49 Million SEK | -574.501% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -3327.716% |
| BioInvent International AB (publ) | 441.4 Million SEK | -243.049% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -6221.329% |
| Alzinova AB (publ) | 36.39 Million SEK | -4060.424% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -422.605% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -19174.136% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -1265.227% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -10200.871% |